CYTX Cytori Therapeutics Inc.

0.26
-0.01  -2%
Previous Close 0.27
Open 0.27
Price To Book 0.55
Market Cap 3417845
Shares 13,201,410
Volume 422,635
Short Ratio
Av. Daily Volume 346,675

Drug Information

Drug catalyst information is displayed when you hover over the stage bar graph.

Pivotal trial data released June 24, 2017 - endpoints not met.
ECCS-50
Scleroderma
Phase 2 interim data released February 2016 noted that the pre-specified primary endpoint did not obtain statistical significance. Full data due 3Q 2016
ECCO-50 cellular therapeutic
Osteoarthritis of the knee
Phase 2 planned.
ATI-1123
Solid Tumors
Phase 2 data estimated 1Q 2019
SCLERADEC II
Scleroderma